Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An International Phase 1/2 Study of GRT-C901/GRT-R902, a Neoantigen Cancer Vaccine, in Combination With Immune Checkpoint Blockade for Patients With Advanced Solid Tumors

NCT03639714 is registered in ClinicalTrials.gov with Gritstone bio, Inc. as lead sponsor.

NCT NCT03639714
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03639714 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An International Phase 1/2 Study of GRT-C901/GRT-R902, a Neoantigen Cancer Vaccine, in Combination With Immune Checkpoint Blockade for Patients With Advanced Solid Tumors
Lead sponsor
Gritstone bio, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
February 13, 2019
Completion date
November 10, 2022
Enrollment
29 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer, gastroesophageal adenocarcinoma, non small cell lung cancer, urothelial carcinoma